Table 1.
Ongoing or planned clinical trial for COVID-19 vaccine up to 11 November 2020
| Candidate | Type | Phase | Study design | Volunteer | Country | Reference |
|---|---|---|---|---|---|---|
| Moderna mRNA-1273 | RNA | 3 | Double-blind randomized | 30000 | USA | NCT04470427 |
| WIBP vaccine | Inactivated | 3 | Double-blind randomized | 45,000 | Bahrain, Jordan, Egypt, UAE | NCT04510207 |
| Sinovac CoronaVac | Inactivated | 3 | Double-blind randomized | 13,060 | Brazil | NCT04456595 |
| Oxford ChAdOx1-S | Non-replicating viral vector | 3 | Double-blind randomized | 40,051 | USA, Chile, Peru | NCT04516746 |
| Novavax NVX-CoV2373 | Protein subunit | 3 | Double-blind randomized | 30,000 | USA, Mexico, Puerto Rico | NCT04611802 |
| Novavax NVX-CoV2373 | Protein subunit | 3 | Double-blind randomized | 9,000 | UK | NCT04583995 |
| Moderna mRNA-1273 | RNA | 3 | Double-blind randomized | 30,000 | USA | NCT04470427 |
| Cansino Ad5-nCoV | Non-replicating viral vector | 3 | Double-blind randomized | 40,000 | Pakistan | NCT04526990 |
| BIBP/ Sinopharm BBIBP-CorV | Inactivated | 3 | Double-blind randomized | 3,000 | Argentina | NCT04560881 |
| Oxford ChAdOx1-S | Non-replicating viral vector | 2/3 | Single-blind randomized | 12,390 | UK | NCT04400838 |
| BioNTech BNT162 | RNA | 2/3 | Dose-finding, double-blind randomized | 43,998 | USA, Argentina, Brazil, others | NCT04368728 |
| BioNTech BNT162 | RNA | 2/3 | Dose-finding, open-label non-randomized | 43,998 | USA, Argentina, Brazil, others | NCT04380701 |
| AZLB protein subunit vaccine | Protein subunit | 2 | Double-blind randomized | 900 | China | NCT04466085 |
| Novavax NVX-CoV2373 | Protein subunit | 2 | Single-blind randomized | 4,400 | South Africa | NCT04533399 |
| Curevac CVnCoV | RNA | 2 | Dose-confirmation,double-blind, randomized | 691 | Peru | NCT04515147 |
| Oxford ChAdOx1-S | Non-replicating viral vector | 1/2 | Double-blind randomized | 2000 | South Africa | NCT04444674 |
| WIBP vaccine | Inactivated | 1/2 | Dose-finding, double-blind randomized | 1,264 | China | ChiCTR2000031809 |
| Bharat Covaxin | Inactivated | 1/2 | Double-blind randomized | 755 | India | NCT04471519 |
| Oxford ChAdOx1-S | Non-replicating viral vector | 1/2 | Single-blind randomized | 1,090 | UK | NCT04324606 |
| Zydus Cadila ZyCoV-D | DNA | 1/2 | Double-blind randomized | 1048 | India | CTRI/2020/07/026352 |
| CAMS vaccine | Inactivated | 1/2 | Dose-finding, double-blind randomized | 942 | China | NCT04412538 |
| Sinovac CoronaVac | Inactivated | 1/2 | Dose-finding, double-blind randomized | 744 | China | NCT04352608 |
| Cansino Ad5-nCoV | Non-replicating viral vector | 1/2 | Dose-finding, double-blind randomized | 696 | Canada | NCT04398147 |
| CAMS vaccine | Inactivated | 1/2 | Double-blind randomized | 471 | China | NCT04470609 |
| Sinovac CoronaVac | Inactivated | 1/2 | Dose-finding, double-blind randomized | 422 | China | NCT04383574 |
| Genexine GX-19 | DNA | 1/2 | Dose-finding, double-blind randomized | 210 | Republic of Korea | NCT04445389 |
| Aivita AV-COVID-19 | Other | 1/2 | Dose-finding, double-blind randomized | 180 | USA | NCT04386252 |
| KBP-COVID-19 | Protein subunit | 1/2 | Observer-blind, dose-finding randomized | 180 | Not Provided | NCT04473690 |
| Inovio INO-4800 | DNA | 1/2 | Dose-finding, Open-label (A), double-blind (B) randomized | 160 | Republic of Korea | NCT04447781 |
| Arcturus ARCT-021 | RNA | 1/2 | Double-blind randomized | 92 | Singapore | NCT04480957 |
| AnGes AG0301-COVID19 | DNA | 1/2 | Dose-finding, Open-label non-randomized | 30 | Japan | NCT04463472 |
| Themis V591 | Replicating viral vector | 1/2 | Dose-finding, double-blind randomized | 260 | USA, Austria, Belgium | NCT04498247 |
| Inovio INO-4800 | DNA | 1/2 | Dose-finding, open-label (A), double-blind (B) randomized | 160 | Republic of Korea | NCT04447781 |
| Novavax NVX-CoV2373 | Protein subunit | 1/2 | Dose-finding, observer-blind randomized | 1,419 | Australia, USA | NCT04368988 |
| Imperial LNP-nCoVsaRNA | RNA | 1 | Dose-finding partially randomized | 320 | UK | ISRCTN17072692 |
| Medicago CoVLP | Virus-like particle | 1 | Dose-finding, open-label randomized | 180 | Canada | NCT04450004 |
| Curevac CVnCoV | RNA | 1 | Dose-finding, single-blind randomized | 284 | Belgium, Germany | NCT04449276 |
| PLA-AMS ARCoV | RNA | 1 | Dose-finding randomized | 168 | China | ChiCTR2000034112 |
| Moderna mRNA-1273 | RNA | 1 | Dose-finding, open-label non-randomized | 120 | USA | NCT04283461 |
| Clover SCB-2019 | Protein subunit | 1 | Dose-finding, double-blind randomized | 150 | Australia | NCT04405908 |
| BioNTech BNT162 | RNA | 1 | Double-blind randomized | 144 | China | NCT04523571 |
| Inovio INO-4800 | DNA | 1 | Dose-finding, open-label non-randomized | 120 | USA | NCT04336410 |
| University of Queensland vaccine | Protein subunit | 1 | Dose-finding, double-blind randomized | 216 | Australia | NCT04495933 |
| Symvivo bacTRL-Spike | DNA | 1 | Dose-finding, observer-blind randomized | 12 | Australia | NCT04334980 |
| Cansino Ad5-nCoV | Non-replicating viral vector | 1 | Dose-finding, open-label non-randomized | 108 | China | NCT04313127 |
| SGMI aAPC | Other | 1 | Open-label non-randomized | 100 | China | NCT04299724 |
| SGMI LV-SMENP-DC | Other | 1 | Open-label non-randomized | 100 | China | NCT04276896 |
| Themis V591 | Replicating viral vector | 1 | Dose-finding, double-blind randomized | 90 | Belgium, France | NCT04497298 |
| Gamaleya Gam-COVID-Vac (Lyo) | Non-replicating viral vector | 1 | Open-label non-randomized | 38 | Russia | NCT04437875 |
| AZLB protein subunit vaccine | Protein subunit | 1 | Double-blind randomized | 50 | China | NCT04445194 |
| Medigen MVC-COV1901 | Protein subunit | 1 | Dose finding, open-label non-randomized | 45 | Taiwan | NCT04487210 |
| Vaxine protein subunit vaccine | Protein subunit | 1 | Double-blind randomized | 40 | Australia | NCT04453852 |
aAPC, artificial antigen presenting cell; AZLB, Anhui Zhifei Longcom Biopharmaceutical; BIBP, Beijing Institute of Biological Products; CAMS, Chinese Academy of Medical Sciences; KBP, Kentucky BioProcessing; LV-SMENP-DC, vaccine comprising dendritic cells (DCs) modified with lentivirus (LV) vectors expressing ‘SMENP’ minigene; PLA-AMS, People’s Liberation Army Academy of Military Science; SGMI, Shenzhen Geno-Immune Medical Institute; WIBP, Wuhan Institute of Biological Products.